These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2123007)

  • 1. Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias.
    Turgeon J; Pavlou HN; Wong W; Funck-Brentano C; Roden DM
    J Pharmacol Exp Ther; 1990 Nov; 255(2):642-9. PubMed ID: 2123007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism.
    Funck-Brentano C; Turgeon J; Woosley RL; Roden DM
    J Pharmacol Exp Ther; 1989 Apr; 249(1):134-42. PubMed ID: 2496225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man.
    Barbey JT; Thompson KA; Echt DS; Woosley RL; Roden DM
    Circulation; 1988 Feb; 77(2):380-91. PubMed ID: 3123092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals.
    Carey EL; Duff HJ; Roden DM; Primm RK; Wilkinson GR; Wang T; Oates JA; Woosley RL
    J Clin Invest; 1984 Feb; 73(2):539-47. PubMed ID: 6421879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition kinetics of encainide and metabolites.
    Roden DM; Wood AJ; Wilkinson GR; Woosley RL
    Am J Cardiol; 1986 Aug; 58(5):4C-9C. PubMed ID: 3092618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Acute and long-term antiarrhythmia effect of encainide in chronic atrial extrasystole].
    Thale J; Klein H; Shanks RG; Bender F
    Z Kardiol; 1985 Apr; 74(4):220-7. PubMed ID: 2408392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of genetic polymorphism on the metabolism and disposition of encainide in man.
    Wang T; Roden DM; Wolfenden HT; Woosley RL; Wood AJ; Wilkinson GR
    J Pharmacol Exp Ther; 1984 Mar; 228(3):605-11. PubMed ID: 6423808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative antiarrhythmic actions of encainide and its major metabolites.
    Gomoll AW; Byrne JE; Mayol RF
    Arch Int Pharmacodyn Ther; 1986 Jun; 281(2):277-97. PubMed ID: 3092755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oxidative metabolism of encainide: polymorphism, pharmacokinetics and clinical considerations.
    McAllister CB; Wolfenden HT; Aslanian WS; Woosley RL; Wilkinson GR
    Xenobiotica; 1986 May; 16(5):483-90. PubMed ID: 3090789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers.
    Turgeon J; Funck-Brentano C; Gray HT; Pavlou HN; Prakash C; Blair IA; Roden DM
    Clin Pharmacol Ther; 1991 May; 49(5):488-96. PubMed ID: 1903098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical pharmacokinetics of encainide.
    Roden DM; Woosley RL
    Clin Pharmacokinet; 1988 Mar; 14(3):141-7. PubMed ID: 3131058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of diltiazem on the disposition of encainide and its active metabolites.
    Kazierad DJ; Lalonde RL; Hoon TJ; Mirvis DM; Bottorff MB
    Clin Pharmacol Ther; 1989 Dec; 46(6):668-73. PubMed ID: 2513160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Encainide disposition in patients with renal failure.
    Bergstrand RH; Wang T; Roden DM; Stone WJ; Wolfenden HT; Woosley RL; Wilkinson GR; Wood AJ
    Clin Pharmacol Ther; 1986 Jul; 40(1):64-70. PubMed ID: 3087679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and metabolism of encainide.
    Jaillon P
    Cardiovasc Drugs Ther; 1990 Jun; 4 Suppl 3():561-5. PubMed ID: 2125833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug interaction studies and encainide use in renal and hepatic impairment.
    Quart BD; Gallo DG; Sami MH; Wood AJ
    Am J Cardiol; 1986 Aug; 58(5):104C-113C. PubMed ID: 2875643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative study of encainide and quinidine in the treatment of ventricular arrhythmias.
    Morganroth J; Somberg JC; Pool PE; Hsu PH; Lee IK; Durkee J; Salerno DM
    J Am Coll Cardiol; 1986 Jan; 7(1):9-16. PubMed ID: 3079781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.
    Turgeon J; Fiset C; Giguère R; Gilbert M; Moerike K; Rouleau JR; Kroemer HK; Eichelbaum M; Grech-Bélanger O; Bélanger PM
    J Pharmacol Exp Ther; 1991 Nov; 259(2):789-98. PubMed ID: 1941626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect.
    Funck-Brentano C; Kroemer HK; Pavlou H; Woosley RL; Roden DM
    Br J Clin Pharmacol; 1989 Apr; 27(4):435-44. PubMed ID: 2719900
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of encainide and its major metabolites, O-demethyl encainide and 3-methoxy-O-demethyl encainide, on experimental cardiac arrhythmias in dogs.
    Kerr MJ; Allen JD; Harron DW; Shanks RG
    J Cardiovasc Pharmacol; 1985; 7(3):449-57. PubMed ID: 2410673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Qualitative and quantitative comparison of the cardiac effects of encainide and its three major metabolites in the dog.
    Davy JM; Dorian P; Kantelip JP; Harrison DC; Kates RE
    J Pharmacol Exp Ther; 1986 Jun; 237(3):907-11. PubMed ID: 3086540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.